I-Mab Biopharma Revenue and Competitors

Shanghai,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • I-Mab Biopharma's estimated annual revenue is currently $30.4M per year.(i)
  • I-Mab Biopharma's estimated revenue per employee is $155,000

Employee Data

  • I-Mab Biopharma has 196 Employees.(i)
  • I-Mab Biopharma grew their employee count by 1% last year.

I-Mab Biopharma's People

NameTitleEmail/Phone
1
Founder and ChairmanReveal Email/Phone
2
US Site Head, VPReveal Email/Phone
3
CEOReveal Email/Phone
4
VP, Head Global Corporate AllianceReveal Email/Phone
5
SVP, U.S. & E.U. Business DevelopmentReveal Email/Phone
6
SVP, OperationsReveal Email/Phone
7
Board Secretary; VP Strategy and PlanningReveal Email/Phone
8
Senior Director, Global Medical SafetyReveal Email/Phone
9
Director operations and Global Alliance ManagementReveal Email/Phone
10
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is I-Mab Biopharma?

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States.

keywords:N/A

N/A

Total Funding

196

Number of Employees

$30.4M

Revenue (est)

1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

I-Mab Biopharma News

2022-04-20 - I-Mab allegedly seeking asset or company sale - BioProcess ...

Shanghai-based I-Mab is in talks with global drugmakers about a ... market for biopharma IPOs has deteriorated greatly over the past year.

2022-04-17 - Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain ...

Pre-Open Stock Movers 04/20: AlloVir, I-Mab Biopharma Gain; Netflix Plunges (more...) April 20, 2022 9:23 AM. Pre-Open Stock Movers: Netflix (NASDAQ: NFLX)...

2022-03-22 - I-Mab Announces Voluntary Lock-ups by Key Shareholders ...

SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46.5M206-1%N/A
#2
$41.6M207-5%N/A
#3
$32.6M212-1%N/A
#4
$39.6M218-9%N/A
#5
$18.8M219-38%$151.1M